Elite Pharma FY2023 revenue $34.2M (+5.9% YoY); operating profit down $1.4M

ELITE PHARMACEUTICALS INC /NV/

FY2023 revenues $34.2M, up 5.9% from prior year; net income $3.6M.
Operating profit $3.7M, a decrease of $1.4M due to higher R&D and sales-distribution investment.
Company will host conference call June 30 at 11:30 AM EDT to discuss results.
Stockholder questions accepted via email prior to the call.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ELITE PHARMACEUTICALS INC /NV/ reported the fiscal year ended March 31, 2023 results: revenue $34.2 million, net income $3.6 million.

Period: the fiscal year ended March 31, 2023
Revenue: $34.2 million
Net income: $3.6 million
Result: reported results

Exact text from the filing

Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2023 (“Fiscal 2023”). Consolidated revenues for Fiscal 2023 were $34.2 million, an increase of $1.9 million or 5.9% as compared to the comparable period of the prior fiscal year. Operating profits were $3.7 million, a decrease of $1.4 million from the comparable period of the prior year, and net income was $3.6 million.

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

ELITE PHARMACEUTICALS INC /NV/ filing history →

Source: SEC EDGAR

accession 0001493152-23-022959

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.